[croshan]

Exactly. I know if medication were to be developed, checking "are GDF15 levels significantly lowered" would be part of the trials.

But how often does the medication development process check the result we care about: "does this medication then go on to reduce the chance of dementia?"

[wbl]

Always. Secondary endpoints are heavily disfavored in FDA approval.